ERBB2 and neoplasm: We developed an EGFRvIII+/HER2+ heterogeneous GBM model to demonstrate that a co-administration of EGFRvIII-DBTE and HER2-DBTE dramatically enhanced tumor suppression in the heterogeneous GBM challenge as compared with single DBTEs.